PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28301850
OWN - NLM
STAT- MEDLINE
DCOM- 20170901
LR  - 20170901
IS  - 1423-0259 (Electronic)
IS  - 0030-3747 (Linking)
VI  - 58
IP  - 1
DP  - 2017
TI  - Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor
      Treatment for Neovascular Age-Related Macular Degeneration.
PG  - 18-26
LID - 10.1159/000459626 [doi]
AB  - PURPOSE: To investigate the effect of vitreomacular adhesion (VMA) on the outcome
      of antiangiogenic treatment for neovascular age-related macular degeneration
      (AMD). METHODS: Ninety-nine eyes of 83 patients were used in our cohort study. We
      prospectively evaluated best corrected visual acuity (BCVA) and central retinal
      thickness (CRT) in patients with neovascular AMD at baseline and 1, 2, 3, 6, and 
      12 months after treatment with anti-vascular endothelial growth factor
      (anti-VEGF) agents. All patients were stratified by spectral domain optical
      coherence tomography into 2 groups (i.e., VMA[+] and VMA[-]) according to the
      presence or absence of VMA, and the response to treatment was evaluated. RESULTS:
      Fifty-four eyes (54.5%) were included in the VMA(-) group and 45 eyes (45.5%)
      comprised the VMA(+) group. In paired comparisons of mean BCVA between baseline
      and each follow-up visit (1, 2, 3, 6, and 12 months), the VMA(-) group showed
      statistically significant improvement at 1, 2, and 3 months compared to baseline,
      and BCVA significantly improved only at 3 months in the VMA(+) group. For both
      groups, paired comparisons of CRT showed a statistically significant decrease
      when data obtained at 1, 2, 3, 6, and 12 months were compared to baseline values 
      (p < 0.05). CONCLUSIONS: Posterior VMA is associated with a worse short-term
      outcome in patients with neovascular AMD treated with anti-VEGF agents.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Kanadani, Tereza Cristina Moreira
AU  - Kanadani TCM
AD  - Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, 
      Brazil.
FAU - Dos Reis Veloso, Carlos Eduardo
AU  - Dos Reis Veloso CE
FAU - Dorairaj, Syril
AU  - Dorairaj S
FAU - Nehemy, Marcio Bittar
AU  - Nehemy MB
LA  - eng
PT  - Journal Article
DEP - 20170317
PL  - Switzerland
TA  - Ophthalmic Res
JT  - Ophthalmic research
JID - 0267442
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 15C2VL427D (aflibercept)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/administration & dosage
MH  - Bevacizumab/*administration & dosage
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Macula Lutea/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Ranibizumab/*administration & dosage
MH  - Receptors, Vascular Endothelial Growth Factor/*administration & dosage
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Time Factors
MH  - Tissue Adhesions/complications/diagnosis
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
MH  - Visual Acuity
MH  - Vitreous Body/*pathology
MH  - Wet Macular Degeneration/diagnosis/*drug therapy/etiology
OTO - NOTNLM
OT  - Antiangiogenic treatment
OT  - Neovascular age-related macular degeneration
OT  - Vitreomacular adhesion
EDAT- 2017/03/17 06:00
MHDA- 2017/09/02 06:00
CRDT- 2017/03/17 06:00
PHST- 2016/08/24 00:00 [received]
PHST- 2017/02/05 00:00 [accepted]
PHST- 2017/03/17 06:00 [pubmed]
PHST- 2017/09/02 06:00 [medline]
PHST- 2017/03/17 06:00 [entrez]
AID - 000459626 [pii]
AID - 10.1159/000459626 [doi]
PST - ppublish
SO  - Ophthalmic Res. 2017;58(1):18-26. doi: 10.1159/000459626. Epub 2017 Mar 17.